CD20-话题@MedSci

#CD20#

37篇内容 | 1653人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2229759, encodeId=3bc12229e59d2, content=<a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a> <a href='/topic/show?id=04481199320c' target=_blank style='color:#2F92EE;'>#难治性或复发性大B细胞淋巴瘤#</a>, objectTitle=【AJH】邹德慧/梁爱斌教授牵头，CD20 CAR-T治疗CD19 CAR-T失败的R/R LBCL的I期研究, objectType=article, longId=846066, objectId=904c84606687, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240920/1726814091434_8538692.jpg, objectUrl=/article/show_article.do?id=904c84606687, replyNumber=0, likeNumber=91, createdTime=2024-10-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=904c84606687, moduleTitle=【AJH】邹德慧/梁爱斌教授牵头，CD20 CAR-T治疗CD19 CAR-T失败的R/R LBCL的I期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904c84606687)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1943822, encodeId=47bd1943822e5, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, objectType=article, longId=728566, objectId=eb89e28566e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e28566e7, replyNumber=0, likeNumber=91, createdTime=2022-07-26, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e28566e7, moduleTitle=2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e28566e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943821, encodeId=475d1943821a6, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=国产“三抗”扛鼎之作！CD3/CD19/CD20三抗中国临床试验获批, objectType=article, longId=293305, objectId=4f17293305d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f17293305d6, replyNumber=0, likeNumber=95, createdTime=2022-08-19, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f17293305d6, moduleTitle=国产“三抗”扛鼎之作！CD3/CD19/CD20三抗中国临床试验获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f17293305d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943820, encodeId=f951194382056, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批, objectType=article, longId=292522, objectId=095329252292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=095329252292, replyNumber=0, likeNumber=74, createdTime=2022-08-22, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=095329252292, moduleTitle=全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=095329252292)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943819, encodeId=5b8a1943819e2, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Nat Med：抗CD20治疗的多发性硬化症患者接种SARS-CoV-2 mRNA疫苗后的细胞和体液免疫应答, objectType=article, longId=217151, objectId=cf5321e1514e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf5321e1514e, replyNumber=0, likeNumber=93, createdTime=2021-11-13, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf5321e1514e, moduleTitle=Nat Med：抗CD20治疗的多发性硬化症患者接种SARS-CoV-2 mRNA疫苗后的细胞和体液免疫应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf5321e1514e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943818, encodeId=0e6d194381865, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, objectType=article, longId=216944, objectId=046e21694492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046e21694492, replyNumber=0, likeNumber=76, createdTime=2022-04-12, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046e21694492, moduleTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046e21694492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943817, encodeId=c840194381e4e, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=JNNP：抗CD20单抗疗法降低多发性硬化症或视神经脊髓炎患者对SARS-CoV-2的体液免疫应答, objectType=article, longId=215532, objectId=d6f5215532da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6f5215532da, replyNumber=0, likeNumber=70, createdTime=2022-01-29, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6f5215532da, moduleTitle=JNNP：抗CD20单抗疗法降低多发性硬化症或视神经脊髓炎患者对SARS-CoV-2的体液免疫应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6f5215532da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943814, encodeId=7470194381464, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=罗氏2款新药在中国获批临床：CD3/CD20双抗、C5单抗, objectType=article, longId=200497, objectId=d56720049e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d56720049e3b, replyNumber=0, likeNumber=0, createdTime=2021-03-03, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d56720049e3b, moduleTitle=罗氏2款新药在中国获批临床：CD3/CD20双抗、C5单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d56720049e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943813, encodeId=33021943813d6, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=再鼎生物CD3/CD20双抗获批5项临床，预计募资10亿美元在港二次上市, objectType=article, longId=200491, objectId=b34220049167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b34220049167, replyNumber=0, likeNumber=81, createdTime=2020-12-16, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b34220049167, moduleTitle=再鼎生物CD3/CD20双抗获批5项临床，预计募资10亿美元在港二次上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b34220049167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943810, encodeId=a9ad19438105c, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, objectType=article, longId=197588, objectId=c63a19e588ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c63a19e588ba, replyNumber=0, likeNumber=100, createdTime=2021-06-22, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c63a19e588ba, moduleTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c63a19e588ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943811, encodeId=42a31943811e6, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, objectType=article, longId=199630, objectId=6d341996303b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d341996303b, replyNumber=0, likeNumber=78, createdTime=2020-11-11, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d341996303b, moduleTitle=Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d341996303b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943816, encodeId=062b194381661, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=75, createdTime=2021-04-25, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943806, encodeId=22e819438061d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠 , objectType=article, longId=193743, objectId=df92193e4370, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df92193e4370, replyNumber=0, likeNumber=85, createdTime=2020-07-01, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df92193e4370, moduleTitle=抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df92193e4370)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943809, encodeId=f1461943809d9, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Blood：采用CD19/CD20 CAR T细胞治疗难治性/复发性非霍奇金淋巴瘤, objectType=article, longId=196286, objectId=035019628601, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=035019628601, replyNumber=0, likeNumber=75, createdTime=2020-12-07, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=035019628601, moduleTitle=Blood：采用CD19/CD20 CAR T细胞治疗难治性/复发性非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=035019628601)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943812, encodeId=138e194381255, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=再鼎1.9亿美元引进再生元CD20xCD3双抗进展，已获批临床, objectType=article, longId=200450, objectId=d9ed2004503b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9ed2004503b, replyNumber=0, likeNumber=88, createdTime=2021-07-10, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9ed2004503b, moduleTitle=再鼎1.9亿美元引进再生元CD20xCD3双抗进展，已获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9ed2004503b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943802, encodeId=c9a71943802eb, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, objectType=article, longId=190017, objectId=0f0519001e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0519001e6d, replyNumber=0, likeNumber=74, createdTime=2020-04-18, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0519001e6d, moduleTitle=BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0519001e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943815, encodeId=a8ee194381541, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效, objectType=article, longId=201580, objectId=a894201580eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a894201580eb, replyNumber=0, likeNumber=72, createdTime=2021-08-31, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a894201580eb, moduleTitle=Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a894201580eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943798, encodeId=3a001943e9816, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=宜明昂科CD20/CD47双抗药物获批进入临床, objectType=article, longId=183838, objectId=4ac7183838c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ac7183838c5, replyNumber=0, likeNumber=85, createdTime=2020-03-04, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ac7183838c5, moduleTitle=宜明昂科CD20/CD47双抗药物获批进入临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ac7183838c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943803, encodeId=04f919438034d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=再生元与再鼎医药合作开发REGN1979（CD20xCD3双特异性抗体），治疗非霍奇金淋巴瘤, objectType=article, longId=191863, objectId=981f191863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=981f191863d9, replyNumber=0, likeNumber=107, createdTime=2020-05-12, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=981f191863d9, moduleTitle=再生元与再鼎医药合作开发REGN1979（CD20xCD3双特异性抗体），治疗非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=981f191863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943807, encodeId=11fd194380e3a, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, objectType=article, longId=194365, objectId=0d90194365fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d90194365fe, replyNumber=0, likeNumber=108, createdTime=2021-02-12, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d90194365fe, moduleTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d90194365fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD20

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#CAR-T# #CD20# #难治性或复发性大B细胞淋巴瘤#

【AJH】邹德慧/梁爱斌教授牵头，CD20 CAR-T治疗CD19 CAR-T失败的R/R LBCL的I期研究

2024-10-08发表于上海

aliceclz (审核中...)

前往app查看评论内容

#CD20#

2022 ASCO：复发或难治性B细胞非霍奇金淋巴瘤中CD20和CD19表达缺失，一项回顾性队列研究

2022-07-26

aliceclz (审核中...)

前往app查看评论内容

#CD20#

国产“三抗”扛鼎之作！CD3/CD19/CD20三抗中国临床试验获批

2022-08-19

aliceclz (审核中...)

前往app查看评论内容

#CD20#

全人源CD20单抗！诺华多发性硬化新药奥法妥木单抗在中国获批

2022-08-22

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Nat Med：抗CD20治疗的多发性硬化症患者接种SARS-CoV-2 mRNA疫苗后的细胞和体液免疫应答

2021-11-13

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！

2022-04-12

aliceclz (审核中...)

前往app查看评论内容

#CD20#

JNNP：抗CD20单抗疗法降低多发性硬化症或视神经脊髓炎患者对SARS-CoV-2的体液免疫应答

2022-01-29

aliceclz (审核中...)

前往app查看评论内容

#CD20#

罗氏2款新药在中国获批临床：CD3/CD20双抗、C5单抗

2021-03-03

aliceclz (审核中...)

前往app查看评论内容

#CD20#

再鼎生物CD3/CD20双抗获批5项临床，预计募资10亿美元在港二次上市

2020-12-16

aliceclz (审核中...)

前往app查看评论内容

#CD20#

罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定

2021-06-22

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Science：CD20单克隆抗体治疗B细胞恶性肿瘤的奥秘

2020-11-11

aliceclz (审核中...)

前往app查看评论内容

#CD20#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2021-04-25

aliceclz (审核中...)

前往app查看评论内容

#CD20#

抗CD20单抗科普：从一代的利妥昔到三代的阿妥珠

2020-07-01

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Blood：采用CD19/CD20 CAR T细胞治疗难治性/复发性非霍奇金淋巴瘤

2020-12-07

仁心济世 (审核中...)

前往app查看评论内容

#CD20#

再鼎1.9亿美元引进再生元CD20xCD3双抗进展，已获批临床

2021-07-10

aliceclz (审核中...)

前往app查看评论内容

#CD20#

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准，用于未经治疗的慢性淋巴细胞白血病

2020-04-18

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Lancet Haematol：CD20单抗Obinutuzumab联合DHAP治疗套细胞淋巴瘤的疗效

2021-08-31

aliceclz (审核中...)

前往app查看评论内容

#CD20#

宜明昂科CD20/CD47双抗药物获批进入临床

2020-03-04

aliceclz (审核中...)

前往app查看评论内容

#CD20#

再生元与再鼎医药合作开发REGN1979（CD20xCD3双特异性抗体），治疗非霍奇金淋巴瘤

2020-05-12

aliceclz (审核中...)

前往app查看评论内容

#CD20#

滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批

2021-02-12

科室
- - 订阅+
  - 更多科室
工具
服务